Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
China
· Delayed Price · Currency is CNY 30.41
+0.55 (1.84%)
Mar 10, 2026, 3:00 PM CST
SHA:688566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 964.93 | 896.53 | 860.93 | 654.73 | 509.69 | Upgrade
|
| Revenue Growth (YoY) | 7.63% | 4.13% | 31.49% | 28.46% | -9.94% | Upgrade
|
| Cost of Revenue | - | 95.26 | 97.18 | 76.17 | 62.12 | Upgrade
|
| Gross Profit | 964.93 | 801.28 | 763.76 | 578.56 | 447.57 | Upgrade
|
| Selling, General & Admin | - | 458.54 | 459.86 | 361.56 | 304.65 | Upgrade
|
| Research & Development | - | 38.65 | 55.77 | 55.18 | 29.28 | Upgrade
|
| Other Operating Expenses | 712.17 | 12.98 | 10.47 | 9.24 | 9.1 | Upgrade
|
| Operating Expenses | 712.17 | 512.43 | 533.31 | 426.71 | 341.26 | Upgrade
|
| Operating Income | 252.76 | 288.85 | 230.44 | 151.85 | 106.32 | Upgrade
|
| Interest Expense | - | -0.13 | -0.11 | -0.38 | - | Upgrade
|
| Interest & Investment Income | - | 5.4 | 12.02 | 17.77 | 21.64 | Upgrade
|
| Other Non Operating Income (Expenses) | 45.45 | -0.11 | -0.14 | -0.07 | -0.11 | Upgrade
|
| EBT Excluding Unusual Items | 298.21 | 294.01 | 242.22 | 169.18 | 127.85 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -1.05 | -1.9 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.01 | - | Upgrade
|
| Asset Writedown | - | -42.24 | - | - | - | Upgrade
|
| Other Unusual Items | - | 2.65 | 7.16 | 5.37 | 4.71 | Upgrade
|
| Pretax Income | 298.21 | 253.36 | 247.48 | 174.53 | 132.56 | Upgrade
|
| Income Tax Expense | 39.55 | 34.39 | 28.71 | 20.27 | 18.22 | Upgrade
|
| Earnings From Continuing Operations | 258.67 | 218.98 | 218.77 | 154.26 | 114.35 | Upgrade
|
| Minority Interest in Earnings | - | 0.35 | 0.32 | 0.4 | 0.55 | Upgrade
|
| Net Income | 258.67 | 219.33 | 219.09 | 154.67 | 114.9 | Upgrade
|
| Net Income to Common | 258.67 | 219.33 | 219.09 | 154.67 | 114.9 | Upgrade
|
| Net Income Growth | 17.94% | 0.11% | 41.65% | 34.61% | -11.42% | Upgrade
|
| Shares Outstanding (Basic) | 199 | 194 | 187 | 186 | 188 | Upgrade
|
| Shares Outstanding (Diluted) | 199 | 194 | 187 | 186 | 188 | Upgrade
|
| Shares Change (YoY) | 2.51% | 3.65% | 0.49% | -1.07% | 11.81% | Upgrade
|
| EPS (Basic) | 1.30 | 1.13 | 1.17 | 0.83 | 0.61 | Upgrade
|
| EPS (Diluted) | 1.30 | 1.13 | 1.17 | 0.83 | 0.61 | Upgrade
|
| EPS Growth | 15.04% | -3.42% | 40.96% | 36.07% | -20.78% | Upgrade
|
| Free Cash Flow | - | 40.76 | -197.87 | -141.98 | 66.77 | Upgrade
|
| Free Cash Flow Per Share | - | 0.21 | -1.06 | -0.76 | 0.35 | Upgrade
|
| Dividend Per Share | - | 0.780 | - | 0.480 | 0.480 | Upgrade
|
| Gross Margin | 100.00% | 89.38% | 88.71% | 88.37% | 87.81% | Upgrade
|
| Operating Margin | 26.20% | 32.22% | 26.77% | 23.19% | 20.86% | Upgrade
|
| Profit Margin | 26.81% | 24.46% | 25.45% | 23.62% | 22.54% | Upgrade
|
| Free Cash Flow Margin | - | 4.55% | -22.98% | -21.68% | 13.10% | Upgrade
|
| EBITDA | 263.36 | 299.45 | 241.65 | 164.6 | 119.3 | Upgrade
|
| EBITDA Margin | 27.29% | 33.40% | 28.07% | 25.14% | 23.41% | Upgrade
|
| D&A For EBITDA | 10.6 | 10.6 | 11.2 | 12.75 | 12.98 | Upgrade
|
| EBIT | 252.76 | 288.85 | 230.44 | 151.85 | 106.32 | Upgrade
|
| EBIT Margin | 26.20% | 32.22% | 26.77% | 23.19% | 20.86% | Upgrade
|
| Effective Tax Rate | 13.26% | 13.57% | 11.60% | 11.62% | 13.74% | Upgrade
|
| Revenue as Reported | - | 896.53 | 860.93 | 654.73 | 509.69 | Upgrade
|
| Advertising Expenses | - | - | - | 153.2 | 121.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.